Condition
Epithelioid Mesothelioma|Pleural Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatoid Mesothelioma
Estimated Enrollment: 116
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment
Study ID Numbers: NCI-2011-02015|S0905|CDR0000665415|U10CA180888|U10CA032102
Study First Received: February 5, 2010
Last Updated: April 5, 2017
Estimated Primary Completion Date: June 2017
Primary Outcome Measures:
Maximum tolerated dose determined if the dose-limiting toxicity rate is less than or equal to 33% according to NCI CTCAE version 4.0 (Phase I)|Progression-free survival (Phase II)|Overall survival (Phase II)|Response (Phase II)|Toxicity assessed using NCI CTCAE version 4.0 (Phase II)
Sponsors and Collaborators:
National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT01064648
